FORM PTO-1449 (Modified) Attorney Docket No. Serial No. 17634-000320 09/083,793 LISTOS PATENTS AND PUBLICATIONS FOR APPLICANT'S Applicants Brian R. Murphy et al. JAN 281997EMENT Group Filing Date May 22, 1998 1643 (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) ALConzelmann, "Genetic manipulation of non-segmented negative-strand RNA viruses, " <u>J. Gen. Virol.</u> 77:381-89 (1996)MΑ Cook et al., "In Vivo antigenic Studies of Parainfluenza Viruses, " Amer. Jour. Hyg. 77:150, 1963. AN Cook et al., "Antigenic Relationships Among the "Newer" Myxoviruses (Parainfluenza), " Amer. Jour. Hyg. 69:250, 1959. ΑO Dimock and Collins, "Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3," <u>J. Virol.</u>:2772-2778, 1993. Durbin et al., "Recovery of Infectious Human Parainfluenza AΡ Virus Type 3 from cDNA, "Virology 235:323-332, 1997. ΑQ Durbin et al., "Minimum protein Requirements for Transcription and RNA Replication of a Minigenome of Human Parainfluenza Virus Type 3 and Evaluation of the Rule of Six," <u>Virology</u> 234:74-78 (1997). Flexner et al., "Prevention of vaccinia virus infection in AR immunodeficient mice by vector-directed IL-2 expression," Nature 33:259-262, 1987. Frank et al. "Comparison of Different Tissue Cultures for AS Isolation and Quantitation of Influenza and Parainfluenza Viruses, " <u>J. Clin. Microbiol.</u> 10:32-6 (1979). Fuerst et al., "Eukaryotic transient-expression system ATbased on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase, " Proc. Natl. Acad. Sci. <u>USA</u> 83:8122-8126, 1986. DATE CONSIDERED EXAMINER

	<u></u>					
FORM PTO-1449 (Modified			Attorney Docket No. 17634-000320	Serial No. 09/083,793		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S CINFORMATION DISCLOSURE			Applicants Brian R. Murphy et al.			
JAN 2 8 1999 STATEMENT			Filing Date May 22, 1998	Group 1643		
OTHER	ART	(INCLUDING AUTH	OR, TITLE, DATE, PERTINENT P	AGES, ETC.)		
M M	AU	Galinski et al., "Molecular cloning and Sequence Analysis of the Human parainfluenza 3 Virus Gene Encoding the L Protein," <u>Virology</u> 165: 499-510, (1988).				
	AV	Galinski et al., "RNA Editing in the Phosphoprotein Gene of the Human Parainfluenza Virus Type 3," <u>Virology 186</u> : 543-50 (1992).				
	AW	Garcin et al., "A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus," EMBO J. 14(24):6087-6094 (1995).				
	AX	Grosfeld et al., "RNA Replication by Respiratory Syncytial Virus (RSV) Is Directed by the N, P, and L Proteins; Transcription Also Occurs under These Conditions but Requires RSV Superinfection for Efficient Synthesis of Full-Length mRNA," J. Virol. 69: 5677-5686 (1995).				
	AY	Hall et al., "Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys," <u>Virus Res. 22(3):173-184</u> , 1992.				
	AZ	Karron et al., "A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children," <u>J. Infect. Dis. 171</u> :1107-1114, 1995.				
	ва	Kast et al., "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," Proc. Natl. Acad. Sci. USA 88:2283-2287 , 1991.				
	ВВ	Kunkel et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Methods Enzymol. 154: 367-382, (1987).				
EXAMINER DATE CONSIDERED 12/11/10/						

FORM PTO-14			Attorney Docket No.	Serial No. 09/083,793		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S PENFORMATION DISCLOSURE STATEMENT		OR APPLICANT'S	Applicants Brian R. Murphy et al.			
			Filing Date May 22, 1998	Group 1643		
JAN OTHER	ART	(INCLUDING AUTH	OR, TITLE, DATE, PERTINENT P	AGES, ETC.)		
			"Recombinant vesicular stom oc. Natl. Acad. Sci. U.S.A. 9			
	BD	Murphy et al., "Failure of Attenuated Temperature- Sensitive Influenza A (H3N2) Virus to Induce Heterologous Interference in Humans to Parainfluenza Type 1 Virus," Infect. Immun. 12:62-8, 1975.				
	BE	Murphy et al., "Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses," <u>Virus Res.</u> 11:1-15 (1988).				
	BF	Murphy et al., "Enhanced pulmonary histopathology is observed in cotton rats immunized with formalininactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization," Vaccine 8(5):497-502, 1990.				
	BG	Palese et al., "Negative-strand RNA viruses: Genetic engineering and application," Proc. Natl. Acad. Sci. U.S.A. 93:11354-58, (1996).				
	вн	Pelet et al., "The P gene of bovine parainfluenza virus 3 expresses all three reading frames from a single mRNA editing site," <u>EMBO J.</u> 10:443-448 (1991).				
	BI	Radecke et al., "Rescue of measles viruses from cloned DNA," EMBO J. 14:5773-5784 (1995).				
	BJ	Ray et al., "Human Parainfluenza virus Induces a Type-Specific Protective Immune Response," <u>J. Infect. Dis.</u> 162:746, 1990.				
	вк	Ray et al., "Temperature-Sensitive Phenotype of the Human Parainfluenza virus Type 3 Candidate Vaccine Strain (cp45) Correlates with a Defect in the L Gene," <u>J. Virol.</u> 70:580-584 (1996).				
EXAMINER	NA	Sa.	DATE CONSIDERED	190		

FORM PTO-1	449 (Modified)	Attorney Docket No.	Serial No. 09/083,793		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE			Applicants Brian R. Murphy et al.			
TATEMENT 2 8 1999			Filing Date May 22, 1998	Group 1643		
1	ART	(INCLUDING AUTH	OR, TITLE, DATE, PERTINENT P	AGES, ETC.)		
OTHER PRADENAMENT	BL	proteins of Se and their cont	al., "Expression of the HN, Fendai virus by recombinant va cribution to protective immun nfections in mice," <u>J. Gen.</u>	ccinia viruses ity against		
	вм	Schnell et al., "Infectious rabies viruses from cloned cDNA," EMBO J. 13:4195-203 (1994).				
	BN	Skiadopoulos et al., "Three Amino Acid Substitutions in the L Protein of the Human Parainfluenza Virus Type 3 cp45 Live Attenuated Vaccine Candidate Contribute to Its Temperature-Sensitive and Attenuation Phenotypes," J. Virol 72(3):1762-1768, 1998.				
	во	Spriggs and Collins, "Sequence analysis of the P and C Protein Genes of Human parainfluenza Virus Type 3: Patterns of Amino Acid Sequence Homology among Paramyxovirus Proteins," <u>J. Gen. Virol.</u> 67 2705-2719, (1986).				
	BP	Stokes et al., "The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain," Virus Res. 25:91-103 1992.				
	BQ	Stokes et al., "The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp 12 and cp 45) derived from the JS strain and human parainfluenza virus type 3 (PIV3)," <u>Virus Res. 30 (1):43-52</u> , 1993.				
	BR	Tanabayashi, K. and Compans, R.W., "Functional Interaction of Paramyxovirus Glycoproteins: identification of a Domain in Sendai Virus HN Which Promotes Cell Fusion," <u>J. Virol.</u> 70:6112-18 (1996).				
EXAMINER	ν.	1.	DATE CONSIDERED 12/1//C/			

FORM PTO-1449 (Modified)			·	Attorney Docket No. 17634-000320	Serial No. 09/083,793		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFERNATION DISCLOSURE			OR APPLICANT'S	Applicants Brian R. Murphy et al.			
C STATEMENT				Filing Date May 22, 1998	Group 1643		
1 L	THER,	ART	(INCLUDING AUTH	OR, TITLE, DATE, PERTINENT P	AGES, ETC.)		
Parainfluenza Hemagglutinin-			Parainfluenza Hemagglutinin- Been Replaced	Recovery of a Fully Viable Chimeric Human Virus (PIV) Type 3 in Which the Neuraminidase and Fusion Glycoproteins Have by Those of PIV Type 1," <u>J. Virol. 72</u> :2955-			
	:	вт	Thomson et al., "Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes," <u>J. Immunol. 157</u> :822, 1996.				
		BU	van Wyke Coelingh et al., "Antigenic and Structural Properties of the Hemagglutinin-Neuraminidase glycoprotein of Human Parainfluenza Virus Type 3: Sequence analysis of Variants Selected with Monoclonal antibodies Which Inhibit Infectivity, Hemagglutination, and Neuraminidase Activities," J. Virol. 61:1473-1477, (1987).				
		BV	van Wyke Coelingh et al., "Antigenic Variation in the Hemagglutinin-Neuraminidase Protein of Human Parainfluenza Type 3 Virus," <u>Virology 143</u> (2):569-582, 1985.				
		BW	Whelan et al., "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones," Proc. Natl.Acad. Sci. USA 92:8388-8392 (1995).				
•							
			<u> </u>				
				· · · · · · · · · · · · · · · · · · ·			
	-			•			
EXAMINER MANU DATE CONSIDERED 12/16/95							

FORM PTO-1449 (Modified)			Attorney Docket No. Serial No. 17634-000320 09/083,793				
LIST OF PATENTS AND			17634-000320 09/083,793 Applicants				
PUBLICATIONS FOR APPLICANTES Applicants INFORMATION DISCLOSURE Brian R. Murphy et al.							
STATEMENT JAN 2 8 1999			Filing Date Group May 22, 1998 1643				
REFERENC	E DESIG	ENATION TRADEMIN	U.S. PATE	NTS			
Examiner	l l					Sub-	
Initial	*	Document No.	Date	Name	Class	Class	
MM	AA	5,716,821	02/10/98	Wertz et al.	435	235.1	
	AB	5,789,229	08/04/98	Wertz et al.	435	235.1	
V		FOREJ	GN PATENT I	DOCUMENTS			
Examiner Initial	*	Document No.	Date	Country	Trans- lation?	Class	
	AC	WO 97/06270	02/20/97	PCT		C12N	
	AD	WO 97/11093	03/27/97	PCT		C07K	
	AE	WO 97/20468	06/12/97	PCT		A01N	
	AF	0 440 219 A1	08/07/91	Europe		C12N	
	AG	0 702 085 A1	03/20/96	Europe		C12N	
ОТН	OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
AH Belshe et al., "Cold Adaptation of Parainfluenza Virus Type 3: Induction of Three Phenotypic Markers," J. Med. Virol. 10:235-42 (1982).							
	AI	Blumberg et al., "Measles Virus L Protein Evidences Elements of Ancestral RNA Polymerase," <u>Virology</u> 164:487- 497 (1988).					
	AJ	Collins et al., "Parainfluenza Viruses," <u>Fields Virology</u> 3rd ed., Lippincott-Raven Publishers, Philadelphia 1205- 1241, (1996).					
	AK	Collins et al., "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development," Proc. Natl. Acad. Sci. USA 92:11563-11567 , 1995.					
EXAMINER Modes		DATE CONSIDERED 12/16/99					